Alnara Pharmaceuticals names new chief business officer

The appointment reflects Alnara’s growing operations as the company prepares to submit a new drug application and commercialize liprotamase, a novel, oral, porcine-free pancreatic enzyme replacement therapy that has already completed a Phase III efficacy trial, the company said.

Mr Gallotto brings to his new role over 20 years of pharmaceutical industry experience, with a focus on strategic planning, commercial and business development, and sales and marketing.

Most recently, Mr Gallotto held the position of senior vice president of operations and corporate development for the company. Prior to joining Alnara, Mr Gallotto served as vice president of strategic planning, business and commercial development at Altus Pharmaceuticals, where he worked from 2001 to 2008.

Alexey Margolin, president and CEO of Alnara, said: “Bob has been instrumental in advancing Alnara’s business development strategy and his promotion to chief business officer is the result of his outstanding efforts since the company’s inception last year. His leadership and commercial expertise will continue to enhance Alnara’s corporate presence and drive our efforts in developing and commercializing treatments for metabolic diseases.”